Highlights from Amyloidosis Conferences 2022

CLINICAL ESSENTIALS ARTICLE

Transthyretin-mediated (ATTR) amyloidosis

3-year acoramidis (AG10) results in ATTR-CM: data from an ongoing OLE

The benefits of tafamidis: is there an age limit?

Vutrisiran efficacy and safety at 18 months: results from the HELIOS-A phase III trial

Managing complications in ATTR-CM

Gene silencing therapies for hereditary ATTR amyloidosis: what do we know and what can we expect?

Top image: Design Cells
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.